SCHEMBL5756991

SCHEMBL5756991

CC(C)[C@@H](NS(=O)(=O)c1ccc2nc(SC3CCCC3)sc2c1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
ALDH1A1 P00352 2/20 0.51
HTT P42858 2/20 0.51
LMNA P02545 1/20 0.51
HSP90AA1 P07900 1/20 0.51
HPGD P15428 1/20 0.51
TSHR P16473 1/20 0.51
MMP12 P39900 11/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALOX15 P16050 2/20 0.48
MMP13 P45452 7/20 0.48
CYP2C9 P11712 1/20 0.47
GAA P10253 1/20 0.47
GPR55 Q9Y2T6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755066 0.91 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1HTTLMNAHSP90AA1
SCHEMBL5757831 0.85 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1HTTLMNAHSP90AA1
SCHEMBL5757339 0.85 PKM (0.56) SMN1; SMN2ALDH1A1HTTLMNAHSP90AA1
SCHEMBL7221233 0.82 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1HTTLMNAHSP90AA1
SCHEMBL5756259 0.82 ALOX15 (0.53) SMN1; SMN2ALDH1A1HTTHPGDTSHR
SCHEMBL5757303 0.81 MMP13 (0.55) SMN1; SMN2ALDH1A1HPGDTSHRMMP12
SCHEMBL5759318 0.80 ALOX15 (0.52) SMN1; SMN2ALDH1A1HTTHPGDTSHR
SCHEMBL5755143 0.80 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1HTTHPGDTSHR
SCHEMBL5758777 0.79 HTT (0.54) SMN1; SMN2ALDH1A1HTTMMP12MEN1
SCHEMBL5758844 0.79 MAPT (0.56) ALDH1A1LMNAHPGDTSHRMMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 SMN1; SMN2 654/4885ALDH1A1 311/4885HTT 3845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.